Samik Das

Samik Das

Auto-generated profile, based on publicly available information

Samik Das

Bioprocess Technologies and Engineering, Biopharmaceutical Development AstraZeneca Gaithersburg Maryland USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
CEChristian Escobar
Christian Escobar
CKChen-Yuan Kao
Chen-Yuan Kao
SDSamik Das
Samik Das
Eleftherios T. PapoutsakisEleftherios T. Papoutsakis
Eleftherios T. Papoutsakis
Platelet transfusions are used to treat idiopathic or drug-induced thrombocytopenia. Platelets are an expensive product in limited supply, with limited storage and distribution capabilities because they cannot be frozen. We have demonstrated that, in vitro, human megakaryocytic microparticles (huMkMPs) target human CD34+ hematopoietic stem and progenitor cells (huHSPCs) and induce their Mk differentiation and platelet biogenesis in the absence of thrombopoietin. In this study, we showed that, in vitro, huMkMPs can also target murine HSPCs (muHSPCs) to induce them to differentiate into megakaryocytes in the absence of thrombopoietin. Based on that, using wild-type BALB/c mice, we demonstrated that intravenously administering 2 × 106 huMkMPs triggered de novo murine platelet biogenesis to increase platelet levels up to 49% 16 hours after administration. huMkMPs also largely rescued low platelet levels in mice with induced thrombocytopenia 16 hours after administration by increasing platelet counts by 51%, compared with platelet counts in thrombocytopenic mice. Normalized on a tissue-mass basis, biodistribution experiments show that MkMPs localized largely to the bone marrow, lungs, and liver 24 hours after huMkMP administration. Beyond the bone marrow, CD41+ (megakaryocytes and Mk-progenitor) cells were frequent in lungs, spleen, and especially, liver. In the liver, infused huMKMPs colocalized with Mk progenitors and muHSPCs, thus suggesting that huMkMPs interact with muHSPCs in vivo to induce platelet biogenesis. Our data demonstrate the potential of huMkMPs, which can be stored frozen, to treat thrombocytopenias and serve as effective carriers for in vivo, target-specific cargo delivery to HSPCs.

12 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SDSamik Das
Samik Das
WTWill Thompson
Will Thompson
Eleftherios T. PapoutsakisEleftherios T. Papoutsakis
Eleftherios T. Papoutsakis
Native and engineered extracellular vesicles (EVs) generated from human megakaryocytes (huMkEVs) or from the human megakaryocytic cell line CHRF (CHEVs) interact with tropism delivering their cargo to both human and murine hematopoietic stem and progenitor cells (HSPCs). 24 hours after intravenous infusion of huMkMPs into NOD- scid IL2Rγ null (NSG™) mice, they induced a nearly 50% increase in murine platelet counts relative to saline control, thus demonstrating the potential of these EVs, which can be stored frozen, for treating thrombocytopenias. PKH26-labeled huMkMPs or CHEVs localized to the HSPC-rich bone marrow preferentially interacting with murine HSPCs. Using engineered huMkEVs or CHEVs, their receptor-mediated tropism for HSPCs was explored to functionally deliver synthetic cargo, notably plasmid DNA coding for a fluorescent reporter, to murine HSPCs both in vitro and in vivo. These data demonstrate the potential of these EVs as a non-viral, HSPC-specific cargo vehicle for gene therapy applications to treat hematological diseases. Native and engineered human megakaryocytic extracellular vesicles for targeted non-viral cargo delivery to blood stem cells (Table of Contents): Graphical Overview: Native and engineered human megakaryocytic extracellular vesicles (huMkEVs) for provide targeted non-viral cargo delivery to blood stem cells. We demonstrate that huMkEVs as a transformational cargo-delivery system to blood stem cells (hematopoietic stem and progenitor cells, HSPCs) in NOD-scid IL2Rγ null (NSG™) mice. Intravenous delivery of native huMkEVs enhances de novo platelet biogenesis by inducing megakaryocytic differentiation of murine HSPCs, thus demonstrating the desirable strong tropism of huMkEVs for murine HSPCs. Based on this tropism, we demonstrate that engineered huMkEVs can deliver functional plasmid-DNA cargo specifically to HSPCs.

29 October 2026 in Biotechnology and Bioengineering
Verified
Journal Article
Open access
DSDavid Scherr
David Scherr
AKAna Kanazir
Ana Kanazir
SDSamik Das
Samik Das
NSNikunj Sharda
Nikunj Sharda
JMJan Martinek
Jan Martinek
JCJon Coffman
Jon Coffman
During bsAb1 purification, precipitate was formed during neutralization of the affinity capture product. This precipitate was removed before loading onto the first polishing column in the Integrated Dynamic Bioprocessing (IDB) platform. The precipitate had a dynamic particle size distribution that caused complex scaling without proper characterization. Herein, the study established a protocol for characterizing downstream precipitate formation and operating a depth filter (Emphaze AEX) like a chromatography column to support continuous purification of bsAb1. The depth filter is “underloaded” with precipitated material, followed by a chase step and the application of sanitization buffers. The sanitization buffers solubilized precipitate bound to the depth filter and controlled bioburden, drastically increasing the filter capacity and helped ensure a closed system. At the bench, the depth filter was cycled 40 times for a total capacity of 10,500 L/m 2 . This capacity is an order of magnitude greater than when the depth filter is loaded to max capacity without any cycling or sanitization. The resulting cycling capacity eases depth filter scale‐up and IDB implementation at the clinical and commercial scale.